The Franklin Lakes, N.J.-based healthcare giant posted losses of -$173 million, or -64¢ per share, on sales of $4.40 billion for the three months ended Sept. 30, for a 39.0% top-line gain compared with fiscal Q4 2017, when profits were $289 million.
Adjusted to exclude one-time items, earnings per share were $2.93, in line with the consensus on Wall Street, where analysts were looking for sales of $4.36 billion.
Full-year profits were $159 million, or 60¢ per share, on sales of $15.98 billion, for a -84.6% bottom-line plunge on sales growth of 32.2% compared with fiscal 2017. Adjusted EPS came in at $11.01, again in line with The Street, which was looking for revenues of $15.95 billion.
“Fiscal 2018 was a historic year for BD with the successful completion of the acquisition of C. R. Bard. We are extremely proud of our strong fourth-quarter and fiscal year results, which demonstrate how agile we can be as an organization while executing concurrently on two transformative acquisitions,” chairman & CEO Vincent Forlenza said in prepared remarks. “We enter fiscal 2019 with continued strong momentum and confidence in our ability to execute on our strategy, deliver on our commitments and create value for our shareholders.”
BD said it expects to post adjusted EPS of $12.05 to $12.15 for fiscal 2019 on sales growth of 8.5% to 9.5%.
BDX shares were off by -4.4% to $227.00 apiece today in pre-market trading.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.